Lugano-based InVirtuoLabs aims to halve development time and costs in pharmaceutical research using artificial intelligence and advanced molecular simulations. The startup has now closed its first funding round of €2.85 million to support further developments and expansion.

总部位于卢加诺的InVirtuoLabs致力于通过人工智能和先进的分子模拟技术，将制药研发的时间和成本减半。这家初创公司现已完成首轮融资，获得285万欧元，以支持进一步的开发和扩展。

At the heart of

在核心位置

InVirtuoLabs

虚拟实验室

' innovation is the Next Generation Virtual Lab, a proprietary platform that uses AI and molecular modeling to identify and optimize drugs with proven precision. This approach allows for doubling success rates compared to current research methods, drastically reducing both costs, currently exceeding €2.4 billion per drug, and development times, currently averaging 12 years..

“创新之处在于下一代虚拟实验室，这是一个使用人工智能和分子建模来识别和优化药物的专有平台，其精准性已得到验证。这种方法可以将成功率提高一倍，相比当前的研究方法，大大降低了成本（目前每种药物超过24亿欧元）和研发时间（目前平均为12年）。”

'Our system is not limited to analysing existing data, but generates and tests billions of new molecules, identifying the best ones for efficacy and safety. We want to accelerate the development of treatments for rare diseases, an area still lacking adequate solutions,' says Gianvito Grasso, Founder and CEO of InVirtuoLabs, and Researcher & Lecturer at IDSIA–Dalle Molle Institute for Artificial Intelligence (USI-SUPSI).

“我们的系统不仅限于分析现有数据，还能生成并测试数十亿种新分子，识别出在功效和安全性方面最佳的分子。我们希望加速罕见病治疗方案的开发，这一领域仍然缺乏足够的解决方案，”InVirtuoLabs创始人兼首席执行官、IDSIA－Dalle Molle人工智能研究所（USI-SUPSI）研究员兼讲师吉安维托·格拉索表示。

.

。

The platform's first major achievement was the development of an innovative protocol for drugs targeting nuclear receptors, key proteins in regulating fundamental processes such as metabolism, cell growth, and inflammatory response. These receptors are involved in over 100 diseases, including metabolic disorders and some cancers.

该平台的首个重大成就是开发了一种针对核受体药物的创新协议，核受体是调控代谢、细胞生长和炎症反应等基本过程的关键蛋白。这些受体与包括代谢紊乱和某些癌症在内的100多种疾病有关。

InVirtuoLabs is already applying this protocol to a receptor involved in high-incidence metabolic diseases, with the aim of accelerating the discovery of new treatments.           .

InVirtuoLabs 已经将此协议应用于一种与高发代谢疾病相关的受体，目的是加速新疗法的发现。

“Since inception, we’ve been adjusting our models while engaging with biotech and pharmaceutical companies of all sizes.” adds Demet Olesen, InVirtuoLabs’ CCO. “These early conversations not only help us sharpen our technology but also ensure we’re addressing real-world industry needs.”

“自成立以来，我们一直在调整我们的模型，同时与各种规模的生物技术和制药公司进行合作。”InVirtuoLabs的首席商务官德梅特·奥莱森补充道。“这些早期的对话不仅帮助我们完善了技术，还确保我们能够满足行业的实际需求。”

The InVirtuoLabs team brings together experts with over 50 years of experience in the pharmaceutical industry, with backgrounds in leading companies such as Pfizer, Novo Nordisk, Baxter, and Helsinn Healthcare, as well as researchers specializing in machine learning.

InVirtuoLabs团队汇集了拥有超过50年制药行业经验的专家，他们背景来自辉瑞、诺和诺德、百特和赫尔辛医疗等领先公司，以及专攻机器学习的研究人员。

With the closing of the first funding round, InVirtuoLabs is now well positioned to achieve further milestones on its roadmap. In the next 18 months, the startup plans rapid expansion, strengthen the team, initiate strategic collaborations, and expand the capabilities of the platform. Several prominent investors worldwide, from London to Zurich, Milan, and Lugano, to Istanbul, Athens, Singapore, and Seattle, support the company's vision of democratizing access to innovative therapies, making drug discovery faster, more precise, and economically sustainable..

随着第一轮融资的结束，InVirtuoLabs目前已经为实现其路线图上的更多里程碑做好了充分准备。在接下来的18个月中，这家初创公司计划快速扩张，加强团队建设，启动战略协作，并扩展平台的能力。从伦敦到苏黎世、米兰、卢加诺、伊斯坦布尔、雅典、新加坡和西雅图，全球多位知名投资者支持公司的愿景，即普及创新疗法的获取途径，使药物研发更快、更精准且经济上可持续。

(Press release/RAN)

（新闻稿/无线接入网）

Image: Freepik

图片来源：Freepik

0

0

Comments

评论

Back to all news

返回所有新闻

Please

请

login

登录

or

或

sign up

注册

to comment.

评论。

Commenting guidelines

评论指南

Send

发送